TORONTO, Feb. 8 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company focused on treatments and diagnostics for brain-wasting diseases, today reported its third quarter operating results and provided an update on the Company’s diagnostic and therapeutic programs.
